Fig. 6: SREBP2 elevates PCSK9 to accelerate atrial fibrosis in vivo. | Cell Death Discovery

Fig. 6: SREBP2 elevates PCSK9 to accelerate atrial fibrosis in vivo.

From: RETRACTED ARTICLE: Anti-fibrotic mechanism of SPP1 knockdown in atrial fibrosis associates with inhibited mitochondrial DNA damage and TGF-β/SREBP2/PCSK9 signaling

Fig. 6

A CCK-8 detection of cell viability in HL-1 cells treated with sh-SREBP2 or combined with oe-PCSK9. B TUNEL detection of apoptosis of HL-1 cells treated with sh-SREBP2 or combined with oe-PCSK9. C Western blot analysis of collagen I and collagen III proteins in HL-1 cells treated with sh-SREBP2 alone or in combination with oe-PCSK9. D HE staining of pathological changes of atrial tissues of Ang II-induced mice treated with sh-SREBP2 or combined with oe-PCSK9. E Masson’s trichrome staining of atrial fibrosis degree in Ang II-induced mice treated with sh-SREBP2 or combined with oe-PCSK9. F IHC analysis of collagen I and collagen III proteins in atrial tissues of Ang II-induced mice treated with sh-SREBP2 or combined with oe-PCSK9. *p < 0.05, compared with Ang II-induced mice treated with sh-NC + oe-NC. # p < 0.05, compared with the Ang II-induced mice treated with sh-SREBP2 + oe-NC. All experiments were repeated three times independently. n = 10 for mice in each group.

Back to article page